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Abstract: Even though endothelial dysfunction is known to play a role in migraine pathophysiology,
studies regarding levels of endothelial biomarkers in migraine have controversial results. Our aim
was to evaluate the role of pentraxin 3 (PTX3) and soluble tumour necrosis factor-like weak inducer of
apoptosis (sTWEAK) as potential biomarkers of endothelial dysfunction in chronic migraine (CM). We
performed a case-control study including 102 CM patients and 28 control subjects and measured serum
levels of markers of endothelial dysfunction (PTX3 and sTWEAK) and inflammation [high-sensitivity
C-reactive protein (hs-CRP)] as well as brachial artery flow-mediated dilation (FMD) during interictal
periods. Interictal serum levels of PTX3 and sTWEAK were higher in CM patients than in controls
(1350.6± 54.8 versus 476.1± 49.4 pg/mL, p < 0.001 and 255.7± 21.1 versus 26.4 ± 2.6 pg/mL, p < 0.0001;
respectively). FMD was diminished in CM patients compared to controls (9.6 ± 0.6 versus 15.2 ± 0.9%,
p < 0.001). Both PTX3 and sTWEAK were negatively correlated with FMD (r = −0.508, p < 0.001 and
r = −0.188, p = 0.033; respectively). After adjustment of confounders, PTX3 remained significantly
correlated to FMD (r = −0.250, p = 0.013). Diagnosis of CM was 68.4 times more likely in an individual
with levels of PTX3 ≥ 832.5 pg/mL, suggesting that PTX3 could be a novel biomarker of endothelial
dysfunction in CM.
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1. Introduction
Migraine is a neurological disorder that involves vascular and neural mechanisms in its
pathophysiology. It is generally recognized that the development of a migraine headache depends on
the activation of sensory afferent fibers of the trigeminal nerve, although the mechanisms leading to this
activation are still unclear [1]. Trigeminal activation results in the release of inflammatory vasoactive
peptides that promote vasodilation of the meningeal vessels and modulate endothelial function. The
inflammatory response represents the key piece of evidence behind the role of endothelial dysfunction
in the pathophysiology of migraine [2].
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A bulk of evidence points to an association between migraine and endothelial dysfunction. Whether
this association is causal or on the contrary—that endothelial dysfunction appears as a consequence of
the disease—remains unclear [3]. The possible association between stroke or some non-atherosclerotic
vascular conditions and migraine supports a role of endothelium in the etiopathogenesis of migraine.
A systematic review [4] has recently analysed the relationship between several vascular biomarkers and
migraine, concluding that there are not clear changes in their levels in patients. Promising biomarkers
demand further investigation in the migraine population, for instance, brachial artery flow-mediated
dilation (FMD). This technique has emerged as the most widely used non-invasive tool to assess
endothelial function [5]. Previous FMD studies in migraineurs during interictal and ictal periods have
shown contradictory results [6–8]. A study performed specifically in patients with chronic migraine
(CM) showed diminished FMD [9].
Information regarding the association between CM and molecular biomarkers of vascular
inflammation is limited. Increased plasma levels of fibrinogen and CRP were observed in patients
with CM [9]. Pentraxin 3 (PTX3) is a member of the long pentraxin family that acts as an acute phase
inflammatory glycoprotein [10]. Two studies have demonstrated higher plasma levels of PTX3 in
migraine patients during attacks when compared to interictal periods [11] or healthy controls [12].
Plasma levels of soluble tumour necrosis factor-like weak inducer of apoptosis (sTWEAK) have
been analysed as potential biomarkers of cardiovascular disease and endothelial dysfunction in
vascular [13–15] and non-vascular diseases [16]. Our group demonstrated higher levels of PTX3 and
sTWEAK in patients with severe periodontitis and CM [17]. Furthermore, we demonstrated that PTX3
and sTWEAK are elevated in CM patients and that high plasma levels of PTX3 can predict a good
response to OnabotulinumtoxinA (OnabotA), which is widely used for the treatment of CM [18].
The aim of this study, therefore, was to investigate the relationship between levels of PTX3 and
sTWEAK and FMD in order to elucidate their potential role as markers of endothelial dysfunction in
CM patients during interictal periods.
2. Experimental Section
Subjects were recruited prospectively from the outpatient Headache Clinic of Department
of Neurology at the Clinical University Hospital of Santiago de Compostela. One hundred and
two individuals diagnosed of CM according to International Classification of Headache Disorders,
3rd edition criteria [19], were selected. Preventive treatment use was allowed. Twenty-eight healthy
subjects without history of migraine or other type of headache were enrolled as a control group.
Control subjects were recruited from the hospital and university staff, students, and general population.
All subjects were older than 18 years old. Clinical variables were recorded, and selected molecular
makers were determined in peripheral blood.
Exclusion criteria included the following: 1) high blood pressure (known high blood pressure
or >2 measurements greater than 140/90 mm Hg); 2) coronary disease (coronary lesions > 50%
determined by angiography, myocardial infarction, angina pectoris, or coronary recanalization);
3) diabetes mellitus (known diabetes mellitus or >2 fasting serum glucose determinations >
126 mg/dL); 4) hypercholesterolemia (pharmacologically treated or fasting serum cholesterol >
200 mg/dL); 5) infectious diseases; 6) chronic inflammatory conditions; 7) severe systemic diseases;
8) oligomenorrhea, polymenorrhea, or polycystic ovarian syndrome; 9) pregnancy or lactation;
10) obesity (body mass index > 30 kg/m2); 11) smoking habit (within the previous 12 months); 12) recent
or chronic consumption of vasoactive drugs (>4 times the medium half-life of the active substance),
including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. No patient
was receiving preventive treatment for any of these conditions.
Written informed consent was obtained from each subject included in the study. The Research
Ethics Committee of the Clinical University Hospital of Santiago de Compostela (Spain) approved the
study (ID NO.: 2016/085). All procedures performed in the study were in accordance with the 1964
Helsinki declaration and its later amendments or comparable ethical standards.
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All subjects filled a complete medical record including demographic data (age, gender) and
personal and family history. Physical examination and clinical results were recorded. For migraineurs,
type of migraine (with or without aura), time of evolution of the migraine (measured in years), intensity
of headaches (measured by the visual analogic scale [VAS]), duration of attacks (quantified in hours),
frequency of headaches (number of days with pain per month) as well as allodynia (>2 points on the
12 item allodynia symptom score, ASC-12) were registered. Clinical parameters were considered as
an average of the patient’s episodes in the previous three months. We recorded possible comorbid
conditions associated with migraine as well as symptomatic and preventive treatments for migraine.
After a screening visit, eligible subjects were invited to perform an ultrasonographic examination
and blood sample extraction. Patients were headache-free from the previous 24 h to the visit. If a
migraine occurred within the following 24 h, measurements were repeated in another headache-free
period. Subjects had not previously consumed anti-inflammatory or analgesic medication in the
previous 24 h to the blood sample extraction. Treatment with prophylactic drugs, when it existed, was
not interrupted to perform the study. Measurements for control subjects and patients were performed
between 10:00 and 11:00 am in a quiet, temperature-controlled room (22–24 ◦C) by a single observer.
Subjects were at rest in the supine position for the previous 10 min.
A blood sample was extracted from the non-dominant forearm. Blood samples were collected
in chemistry test tubes, centrifuged at 3000 ×g for 15 min, and immediately frozen and stored at
−80 ◦C. Serum levels of PTX3 and sTWEAK (Assay Biotech, Sunnyvale, CA, USA) were measured
using commercial ELISA kits following manufacturer instructions. High sensitivity C-reactive protein
(hs-CRP) was measured with an immunodiagnostic IMMULITE 1000 System (Siemens Healthcare
Global, Los Angeles). The intra-assay and inter-assay coefficients of variation for all molecular markers
were <8%. Determinations were performed in a laboratory blinded to clinical data.
After blood collection, the ultrasonographic study was completed in the dominant forearm. FMD
of the brachial artery was assessed in all patients by the same researcher (A.L.-F.). The researcher was
blinded to biochemical and molecular determinations and underwent previous technical training and
validation of data (compared with medical staff skilled in neurosonology). We used a high-resolution
B-mode ultrasound device (Aplio 50 Toshiba SSA-700) with a 7.5-MHz linear array transducer. FMD
evaluations were performed according to the International Brachial Artery Reactivity Task Force and
the Working Group of the European Society of Hypertension guidelines [20]. The dominant brachial
artery was imaged 3–5 cm proximal to the antecubital fossa in a longitudinal plane, perpendicular to the
ultrasound beam. Baseline measurements were first performed (d1, as the mean of 5 artery diameter
determinations during systole) and location marked, followed by a rapid inflation of a cuff placed
around the proximal forearm to 300 mm Hg for 4 min. Then a new determination was performed (d2,
as the mean of new 5 determinations of the artery diameter during systole) 45–60 s after cuff release
causing a reactive hyperemia. Brachial artery diameters were obtained from the near-to-far blood
wall intima-media interfaces. FMD was expressed as the percentage of increase in the diameter from
baseline (d2-d1/d1 ×100).
A formal sample size calculation was not done. However, considering a minimum expected effect
size of 874.5 ± 108.0 pg/mL and including 102 CM cases and 28 controls, a post hoc power analysis
calculation using the Macro !NSize for PASW Statistics (http://www.metodo.uab.cat/macros.htm.) was
carried out, showing that our study had a power of 96% with an alpha risk of 5% to demonstrate
significant differences between chronic migraineurs and healthy controls regarding the primary
outcome of the study (i.e., PTX3 serum levels). Mean values ± standard error (SE) and median (P25,
P75) were calculated for normally and non-normally distributed continuous variables, respectively.
Statistical tests used to compare continuous data were the independent t-test or Mann-Whitney U test.
Categorical variables were reported as percentages and compared by chi-square test. Analysis of
covariance (ANCOVA) was used to create adjusted models using age, gender and BMI as covariates
to compare mean values of FMD and biomarkers between cases and controls. Non-parametric
correlation analysis between FMD, biomarkers and clinical variables was performed using Spearman’s
rank correlation coefficient. In addition, partial correlations adjusted for same common confounders
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were also performed for FMD and significant biomarkers. The area under the Receiver Operating
Characteristic (ROC) curve was performed to calculate a cut-off point for PTX3 in order to discriminate
participants with and without CM. Logistic regression analysis was conducted to test the association
between PTX3 (categorized according to calculated cut-off point) and diagnosis of CM adjusted for
potential confounders (age, gender and BMI). All tests were carried out at a significance level of
α = 0.05 using IBM SPSS Statistics (version 24.0, IBM Corp., Armonk, NY, USA).
3. Results
Baseline characteristics of the study population are shown in Table 1. No significant differences
were found between CM patients and controls in terms of age, sex or BMI. Regarding migraine-related
variables, almost half of CM patients presented aura. Allodynia was present in 32.4% of subjects. The
average number of headache days in CM patients was 17.5 days per month with a mean duration of
21 h for each migraine attack. Intensity was recalled as high for most attacks. The number of years
since first migraine symptoms was on average 16.
Table 1. Baseline characteristics of the study population.
Variables Controls (N = 28) CM (N = 102) p-Value
Age (years) 37.3 ± 1.6 39.5 ± 1.2 0.382
Gender, Females, n (%) 26 (92.9) 96 (94.1) 0.682
BMI (kg/m2) 24.3 (22.6, 25.9) 24.8 (22.3, 28.0) 0.474
Frequency of attacks (days/month) 17.5 ± 0.8
Intensity of migraine attacks (VAS) 9.0 (8.0, 10.0)
Duration of migraine attacks (hours) 21.3 ± 3.8
Time of evolution of migraine (years) 15.9 ± 1.2
Aura, n (%) 45 (44.1)
Allodynia, n (%) 33 (32.4)
CM: chronic migraine; BMI: body mass index; VAS: visual analogue scale.
FMD was significantly diminished in patients with CM compared to controls (9.6 ± 0.6 versus
15.2 ± 0.9, p < 0.001) (Figure 1A). Higher circulating levels of PTX3 and sTWEAK were found in CM
compared to those without CM (1350.6 ± 54.8 versus 476.1 ± 49.4 pg/mL, p < 0.001 and 255.7 ± 21.1
versus 26.4 ± 2.6 pg/mL, p < 0.001; respectively) (Figures 1B and 1C). These differences were confirmed
in the multivariate model after adjusting for age, gender and BMI. No significant differences were
observed for hs-CRP between groups (0.1 ± 0.03 mg/dL versus 0.3 ± 0.05 mg/dL, p = 0.178) (Figure 1D).
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Both PTX3 and sTWEAK were negatively correlated with FMD (r =−0.508, p < 0.001 and r = −0.188,
p = 0.033; respectively) (Figure 2A,B). No significant correlations were found between FMD, PTX3,
sTWEAK and clinical or biochemical parameters (Table 2). After adjustment of confounders, PTX3
remained significantly correlated to FMD (r = −0.250, p = 0.013) while adjusted correlation between
sTWEAK and FMD was attenuated, losing statistical significance (r = 0.005, p = 0.962).
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p-value 0.722 0.059 0.890 0.076 0.225 0.63 0.078
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BMI: body mass index; FMD: flow-mediated dilation; PTX3: pentraxin 3; sTWEAK: soluble fragment of tumor
necrosis factor-like weak inducer of apoptosis; hs-CRP: high sensitivity C-reactive protein.
The ROC (receiver operating characteristic) analysis for PTX3 had an area under the curve of 0.928
(95% CI: 0.884–0.971, p < 0.001), which suggests that this approach could discriminate between those
patients with and without CM. The cut point of 832.5 pg/mL of PTX3 produced the optimal sensitivity
and specificity of 83% and 85%, respectively and 86.9% of the participants were correctly assigned
overall with an ORadjusted of 68.4 (which means that CM is 68.4 times more likely in an individual ith
serum levels of PTX3 ≥ 832.5 pg/mL).
4. Discussion
In the present study, CM patients showed altered FMD (a direct measure of endothelial function)
compared to healthy controls. Levels of PTX3 and sTWEAK were higher in CM patients and PTX3
levels were negatively correlated with FMD, even after adjustment for potential confounders. PTX3
serum levels ≥ 832.5 pg/mL independently predicted diagnosis of CM with a sensitivity of 83% and
a specificity of 85%. Our results suggest that PTX3 could be a potential biomarker of endothelial
dysfunction in CM.
The role of gender and sexual hormones in migraine and migraine chronification has been
extensively studied [21]. Several studies have also evaluated the relationship between BMI and
migraine. A higher risk for migraine has been reported in obese subjects and specifically for chronic
migraine either in obese or pre-obese subjects [22]. This association is likely mediated by gender. In our
study there were no differences among groups regarding sex or BMI, and differences observed in PTX3
levels survived multivariate analysis considering these factors.
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To date, several studies have focused on endothelial dysfunction in migraine, however, their
findings are controversial. Related molecular markers such as endothelin-1 (ET-1) or nitric oxide
(NO) have been determined in migraine [23,24]. A systematic review has evaluated more than 600
reports measuring levels of biomarkers of inflammation, prothrombotic state, endothelial activation
and endothelial repair [4] in migraine and concluded that results are conflicting and there are not
definite vascular biomarkers in migraine patients. In the following years, novel potential markers of
endothelial dysfunction were brought up and evaluated, such as endothelial microparticles (EMPs) [25],
asymmetric dimethylarginine (ADMA) [26,27], and endothelial progenitor cells (EPCs) [28,29]. These
molecules and cells play a role in endothelial regeneration and repair of injured vessels. However,
to date, none of these biomarkers have been proven to be associated with vascular endothelial
dysfunction specifically in migraine patients.
FMD is a reproducible and non-invasive ultrasound assessment of endothelial function [5]. Many
studies assessing endothelial function in migraineurs have used FMD, however, their findings have
been inconsistent [30–32]. In a previous study performed by our group, we did not find significant
differences in FMD between control subjects and patients with episodic migraine (EM) during interictal
and ictal periods. In the present study, however, we studied FMD in CM and found that it was
significantly diminished when compared to controls, in agreement with a previous report [9]. FMD
shows a high variability, and single determinations may reflect a transitory response of the endothelium
more than a long-term process of endothelial dysfunction. Recurrent migraine attacks could influence
persistent damage to the endothelium, explaining the different findings between CM and EM patients.
PTXs, a superfamily of soluble, multifactorial, pattern recognition proteins [33,34], are classical
mediators of inflammation and markers of acute-phase reaction. PTXs are an essential component of
the humoral response in innate immunity. In addition to CRP, the PTX superfamily includes the long
PTX3, which is emerging as a key player in immunity and inflammation [35]. Unlike CRP, which is
primarily synthesized in the liver, PTX3 is released by vascular endothelial cells and macrophages after
stimulation with inflammatory cytokines (IL-1β, TNF-α), TLR agonists and microbial components.
Therefore, PTX3 levels are believed to be a true independent indicator of local inflammation and are
thought to reflect endothelial dysfunction more accurately than CPR [12]. Its concentration increases
rapidly in various infections and plays an important role in the early phase of inflammation. PTX-3
can be used as a prognostic biomarker in sepsis and septic shock in adults [36] and children [37].
PTX3 plasma levels are also increased in some non-infectious conditions that involve inflammation
and endothelial damage, such as vascular atherosclerosis, inflammation or vascular damage [38–41],
especially after myocardial infarction [42], reflecting the extent of tissue damage. PTX3 has been
associated with the incidence of coronary artery disease (CAD) and all-cause mortality in CAD
patients [43]. Moreover, in patients with coronary artery disease, plasma levels of PTX3 have been
correlated with endothelial function assessed by FMD showing a stronger association than the one
existing between CRP and endothelial function [10], and it has been suggested that it might play a
protective role in atherosclerosis [43].
Regarding migraine, only two studies have demonstrated higher plasma levels of PTX3 measured
during attacks and compared to interictal periods [11] and control subjects [12]. To date, no information
is available regarding peripheral blood biomarkers of vascular inflammation specifically in CM. Our
group has reported higher levels of PTX3 and sTWEAK in patients with CM and concurrent severe
periodontitis [17] as well as higher levels of PTX3 and sTWEAK in CM patients. On top of that, we
found that PTX3 could be a predictor of a good response to OnabotA, which is widely used for the
treatment of CM [18]. The present study follows this line of research and shows that plasma PTX3 is
significantly correlated with endothelial function assessed by FMD in patients with CM, pointing to
this as the most probable underlying mechanism. Furthermore, PTX levels ≥ 832.5 pg/mL predicted
diagnosis of CM, thus indicating the potential role of PTX3 as a potential biomarker of endothelial
dysfunction in CM.
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TWEAK is a member of the TNF superfamily of cytokines that is synthesized as a type-II
transmembrane protein from which a soluble form with biological activity can be released
(i.e., sTWEAK) [44]. TWEAK mRNA is expressed in a variety of tissues and cells, including brain, heart,
and lung, as well as human endothelial and smooth muscle cells [45]. TWEAK binds to Fn14, a highly
inducible cell-surface receptor that is linked to several intracellular signalling pathways, including
the nuclear factor-κ B (NF-κB) pathway [46]. TWEAK is a multifaceted cytokine whose effects are cell
type and environment-dependent [47]. It may induce various cellular responses in vitro including cell
proliferation [48], migration, differentiation [49], angiogenesis [48], and expression of pro-inflammatory
molecules such as IL-8, MPC-1, ICAM-1, and E-selectin in human umbilical endothelial cells [50], and
IL-6, IL-8, and ICAM-1 in astrocytes [51]. Plasma levels of sTWEAK have been evaluated as potential
biomarkers of cardiovascular disease and endothelial dysfunction within several diseases. Low plasma
levels of sTWEAK were associated with chronic vascular damage in carotid stenosis [13], coronary
artery disease [52], peripheral artery disease [15], heart failure [14], and chronic kidney disease [45],
and in patients with vascular risk factors such as diabetes [16], or hypertension [53]. In contrast,
high plasma levels of sTWEAK have been described in patients after myocardial infarction [54] and
stroke [55]. FMD has been associated with sTWEAK concentration in patients with chronic kidney
disease [45]. The association of sTWEAK with FMD suggests that this protein could also be a biomarker
of endothelial dysfunction.
In our study, we hypothesized that patients with migraine show increased levels of PTX3 and
sTWEAK as a result of altered endothelial function, even in the absence of vascular risk factors. A recent
review has found data supporting a relation between hypertension, transient ischemic attack (TIA),
stroke, hypercholesterolemia and migraine, therefore we excluded subjects with the most prevalent
vascular risk factors and other variables that may influence endothelium integrity and still found higher
levels of PTX3 and sTWEAK in CM patients. Regarding systemic disease and its influence on CM, some
chronic inflammatory conditions have been linked to migraine, such as endometriosis or gastrointestinal
disorders. Systemic autoimmune diseases such as lupus, antiphospholipid syndrome and systemic
sclerosis are more frequent in patients suffering from migraine, and endothelial dysfunction is the
only alteration that is common among all these disorders. Considering that our exclusion criteria
eliminated these confounders, it is tempting to postulate that high levels of PTX3 and sTWEAK are
a result of pathophysiologic mechanisms related to migraine rather than a consequence of other
conditions associated with endothelial dysfunction. These findings suggest a strong link between
migraine, inflammation and endothelial dysfunction. Furthermore, no correlation was found between
plasma levels of PTX3 and sTWEAK registered during interictal period and clinical parameters
(intensity, duration of the headaches, time of evolution of migraine). These findings suggest that
endothelial dysfunction could be a phenomenon related with the specific mechanisms underlying CM
pathophysiology and not with the clinical variability of its manifestations.
This study has several limitations. First, the sample size was relatively small, particularly in
the control group, and a larger population could have powered our results. FMD was studied only
once in each subject when it is known to be variable between different measures, and the examiner
who assessed FMD was not blinded for clinical data. The stage of the menstrual cycle was not taken
into account and it has been proven to have an influence in endothelial function. Although our
exclusion criteria support a relationship between endothelial dysfunction and migraine independently
of cardiovascular cofounders, it also may limit the external validity of our findings.
5. Conclusions
In conclusion, patients with CM had increased circulating levels of PTX3 and sTWEAK as well
as diminished FMD compared to subjects without migraine. PTX3 concentrations are negatively
correlated with FMD. A value of PTX3 ≥ 832.5 pg/mL independently predicted the presence of CM.
Hence, PTX3 could be considered as a potential biomarker of vascular endothelial dysfunction in CM.
Further longitudinal studies are needed to confirm our preliminary results. Intervention studies are
J. Clin. Med. 2020, 9, 849 8 of 11
warranted to investigate whether a reduction in this biomarker could be translated into a beneficial
clinical effect in chronic migraineurs.
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